Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT ID: NCT00003707

Last Updated: 2012-06-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-10-31
• Study Completion Date: 2002-11-30

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase I trial to study the effectiveness of combining R115777 with gemcitabine in treating patients with advanced cancer.

Detailed Description

OBJECTIVES:

• Determine the maximum tolerated dose and dose limiting toxicities of tipifarnib in combination with gemcitabine in patients with advanced cancer.
• Investigate potential pharmacokinetic interactions between tipifarnib and gemcitabine in these patients.
• Determine the efficacy of this regimen in patients with measurable or evaluable disease.
• Evaluate the quality of life of these patients.

OUTLINE: This is a dose-escalation study of tipifarnib.

Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral tipifarnib every 12 hours beginning on day 2. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients each receive escalating doses of tipifarnib until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which fewer than one third of the patients experience dose limiting toxicity.

Quality of life is assessed before treatment, on day 22 of each course, and at the end of treatment.

PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for this study.

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

gemcitabine hydrochloride

Intervention Type: DRUG

tipifarnib

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Pathologically proven advanced cancer for which no curative therapy exists

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Absolute neutrophil count greater than 1,500/mm^3
• Platelet count greater than 100,000/mm^3
• Hemoglobin greater than 9 g/dL

Hepatic:

• Bilirubin normal
• SGOT and SGPT no greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)

Renal:

• Creatinine normal

Other:

• Unassisted oral or enteral intake sufficient to maintain a reasonable state of nutrition
• No concurrent medical condition that is likely to interfere with study participation
• No active visual disturbances that require intervention beyond corrective lenses
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior bone marrow transplantation
• No concurrent immunotherapy

Chemotherapy:

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No prior high dose chemotherapy with bone marrow or stem cell rescue
• No other concurrent chemotherapy

Endocrine therapy:

• No concurrent hormone therapy (except megestrol acetate)

Radiotherapy:

• At least 4 weeks since prior radiotherapy
• No prior radiotherapy to 25% or more of bone marrow
• No concurrent radiotherapy (except palliative radiotherapy within the first 28 days of the study)

Surgery:

• Not specified

Other:

• At least 30 days since prior investigational therapy
• No concurrent investigational therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

The University of Texas Health Science Center at San Antonio

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric K. Rowinsky, MD

Role: STUDY_CHAIR

San Antonio Cancer Institute

Locations

San Antonio Cancer Institute

San Antonio, Texas, United States

Countries

United States

Other Identifiers

P30CA054174

Identifier Type: NIH

Identifier Source: secondary_id

View Link

UTHSC-9785011335

Identifier Type: OTHER

Identifier Source: secondary_id

JRF-R115777-USA-4A

Identifier Type: OTHER

Identifier Source: secondary_id

SACI-IDD-98-03

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-V98-1501

Identifier Type: OTHER

Identifier Source: secondary_id

CDR0000066815

Identifier Type: -

Identifier Source: org_study_id